DFX Intelligence

Data Factory

Private equityFirmbuyoutmiddle market

Abingworth Management Inc.

Private Equity

Menlo Park, CA

We are Abingworth, a trans-atlantic bio-science investment firm with a deep understanding of both the science and markets we invest in.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:b8a847c0-df2f-4096-9410-32561d4447f4

Data as of Sep 15, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 3:50 AM UTC and rebuilt at most every 15 minutes.

Relationships: 52
Dated events: 40
On other graphs: 2
Observed: Sep 13, 2026 to Sep 15, 2026
28 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Venture Capitalidentity

Abingworth Management Inc.

Venture manager · shared crd

RIA / Wealth Managementidentity

ABINGWORTH MANAGEMENT INC.

Registered adviser · shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 10
PE funds: 10
Vintages: 2015 to 2024
PE GAV, 2024 filing: $57.5Mgross asset value on Form ADV; never dry powder
Regulatory AUM: $1.7B
Investments: 1
Active investments: 0
Size band: MIDDLE MARKETderivedproxy: $1.73bn Private Equity Fund GAV on the Form ADV filed 2022-10-31
Stated sectors: technology
Latest ADV filing: Oct 31, 2022
Employees (ADV): 24
Website: abingworth.com

Funds

Fund	Vintage	Lifecycle	ADV type	Form D sold	GAV
Abingworth Clinical Co-Development Co-Investment Fund	2024	Unknown	Private Equity Fund	n/a	$57.5M
ABV 8 Strategic Uk LP	2021	Unknown	Private Equity Fund	n/a	$7.5M
Abingworth Clinical Co-Development Fund 2 Co-Investment LP	2021	Unknown	Private Equity Fund	n/a	$24.8M
Abingworth Clinical Co-Development Fund 2 LP	2021	Unknown	Private Equity Fund	n/a	$573M
Abingworth Bioventures 8 LP	2020	Harvest	Private Equity Fund	n/a	$439M
Abingworth Bioventures VII LP	2017	Unknown	Private Equity Fund	n/a	$304M
Abingworth Clinical Co-Development Fund LP	2016	Harvest	Private Equity Fund	n/a	$125M
Abingworth Bioventures V Co-Invest Growth Equity Fund LP	2015	Mature	Private Equity Fund	n/a	$10.8M
Abingworth Bioventures V LP	2015	Harvest	Private Equity Fund	n/a	$15.0M
Abingworth Bioventures VI LP	2015	Harvest	Private Equity Fund	n/a	$232M

Investments

Company	State	Role	Control	Invested	Exited	Status
Ether	n/a	unknown	unknown	n/a	n/a	unknown

Relationships

Manages (10)

→ Abingworth Clinical Co-Development Co-Investment FundFund
factNews and newswire
→ Abingworth Bioventures V LPFundVenture Capital Fund
Sep 28, 2015 to presentfactForm ADV
→ Abingworth Bioventures VI LPFundVenture Capital Fund
Sep 28, 2015 to presentfactForm ADV
→ Abingworth Clinical Co-Development Fund LPFundVenture Capital Fund
Sep 30, 2016 to presentfactForm ADV
→ Abingworth Bioventures VII LPFundVenture Capital Fund
Sep 29, 2017 to presentfactForm ADV
→ Abingworth Bioventures 8 LPFundVenture Capital Fund
Sep 26, 2020 to presentfactForm ADV
→ Abingworth Clinical Co-Development Fund 2 Co-Investment LPFundPrivate Equity Fund
Oct 1, 2021 to presentfactForm ADV
→ Abingworth Clinical Co-Development Fund 2 LPFundPrivate Equity Fund
Oct 1, 2021 to presentfactForm ADV
→ ABV 8 Strategic Uk LPFundPrivate Equity Fund
Oct 1, 2021 to presentfactForm ADV
→ Abingworth Bioventures V Co-Invest Growth Equity Fund LPFundVenture Capital Fund
Sep 28, 2015 to presentfactForm ADV

Employs (25)

→ Emma O'ReillyPersonEmma O'ReillyGeneral Counsel
factThe subject's own site
→ Anna SlezakPersonAnna SlezakSenior Associate
factThe subject's own site
→ Helen LiuPersonHelen LiuSenior Associate, CCD
factThe subject's own site
→ Ankur ShahPersonAnkur ShahVice President, CCD
factThe subject's own site
→ Vincent MilesPersonVincent MilesExecutive Director
factThe subject's own site
→ Tim HainesPersonTim HainesExecutive Partner
factThe subject's own site
→ Travis WilsonPersonTravis WilsonManaging Director, CCD
factThe subject's own site
→ Robert DeBenedettoPersonRobert DeBenedettoManaging Director, CCD
factThe subject's own site
→ Andrew SinclairPersonAndrew SinclairManaging Director, Head of Publics & Late Stage
factThe subject's own site
→ Jayson PunwaniPersonJayson PunwaniManaging Director, Head of Venture
factThe subject's own site
→ Bali MuralidharPersonBali MuralidharGlobal Head of Life Sciences & CIO
factThe subject's own site
→ Kurt von EmsterPersonKurt von EmsterManaging Partner
factThe subject's own site
→ Konrad Hans von EmsterPersonPresident/Director Of Abingworth Management Inc
Jan 1, 2015 to presentfactForm ADV
→ Neil Antony CooperPersonDirector Of Abingworth Management Inc
Dec 1, 2019 to presentfactForm ADV
→ John Grayson HeardPersonCco/Secretary Of Abingworth Management Inc.
Feb 1, 2007 to presentfactForm ADV
→ Jonathan James MacquittyPersonDirector
May 1, 1999 to Sep 26, 2014inferenceForm ADV
→ Michael Francis BighamPersonDirector
Apr 1, 2003 to Feb 26, 2015inferenceForm ADV
→ Quentin Lionel Genghis Lloyd-HarrisPersonOwner Of Abingworth Llp
Mar 1, 2008 to Sep 2, 2022inferenceForm ADV
→ Timothy John HainesPersonOwner Of Abingworth Llp
Mar 1, 2008 to Sep 2, 2022inferenceForm ADV
→ Brian Michael GallagherPersonTreasurer/Director Of Abingworth Management Inc
Dec 1, 2019 to Sep 2, 2022inferenceForm ADV
→ David Frederick James LeathersPersonOwner Of Abingworth Management Holdings Limited
Aug 1, 1989 to Nov 5, 2020inferenceForm ADV
→ Stephen William BuntingPersonOwner Of Abingworth Management Holdings Limited
Aug 1, 1989 to Nov 5, 2020inferenceForm ADV
→ Kenneth Harold HaasPersonPresident/Director Of Abingworth Management Inc
Feb 1, 2014 to Dec 21, 2019inferenceForm ADV
→ James Foster AbellPersonDirector Of Abingworth Management Inc
Sep 1, 2000 to Dec 21, 2019inferenceForm ADV
→ Joseph AndersonPersonPartner Of Abingworth Llp
Mar 1, 2008 to Sep 30, 2016inferenceForm ADV

Invested in (1)

→ EtherCompanyunknown
factThe subject's own site

Firm member (1)

→ Carlyle GroupFirmadviser
factDFX's own graph

Owns (11)

← Abingworth LLPFirmOwner Of Abingworth Management Inc
Nov 1, 2008 to presentfactForm ADV
← Carlyle Holdings I, L.P.FirmMember
Jan 1, 2020 to presentfactForm ADV
← Carlyle Holdings I GP Sub L.L.C.FirmGeneral Partner
Nov 1, 2011 to presentfactForm ADV
← Carlyle Holdings I GP Inc.FirmMember
Nov 1, 2011 to presentfactForm ADV
← The Carlyle Group L.P.FirmMember
Jan 1, 2020 to presentfactForm ADV
← Carlyle Holdings II, L.P.FirmMember
Jan 1, 2020 to presentfactForm ADV
← Carlyle Holdings II GP L.L.C.FirmMember
Nov 1, 2011 to presentfactForm ADV
← Carlyle Genesis Uk LLCFirmOwner
Aug 1, 2022 to presentfactForm ADV
← Carlyle Investment Management L.L.C.FirmMember
Jan 1, 2016 to presentfactForm ADV
← TC Group, L.L.C.FirmMember
Dec 1, 2000 to presentfactForm ADV
← CG Subsidiary Holdings L.L.C.FirmMember
Jan 1, 2020 to presentfactForm ADV

Dated events

1 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Aug 28, 2026
Firm news
28 August 2026Redx Announces Close of Series A Financing of $36 Million and Strengthened Board Composition
The subject's own siteobserved 3 days ago
Occurred
Jul 20, 2026
Firm news
20 July 2026Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
The subject's own siteobserved 3 days ago
Occurred
Jul 15, 2026
Firm news
15 July 2026AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure
The subject's own siteobserved 3 days ago
Occurred
Jul 8, 2026
Firm news
8 July 2026Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers
The subject's own siteobserved 3 days ago
Occurred
Jul 6, 2026
Firm news
6 July 2026Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
The subject's own siteobserved 3 days ago
Occurred
Apr 6, 2026
Firm news
6 April 2026Neurocrine to Acquire Soleno Therapeutics
The subject's own siteobserved 3 days ago
Occurred
Jan 7, 2026
Firm news
7 January 2026Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
The subject's own siteobserved 3 days ago
Occurred
Nov 17, 2025
Firm news
17 November 2025AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth
The subject's own siteobserved 3 days ago
Occurred
Sep 22, 2025
Firm news
22 September 2025ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
The subject's own siteobserved 3 days ago
Occurred
Jul 9, 2025
Firm news
9 July 2025Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
The subject's own siteobserved 3 days ago
Occurred
Mar 5, 2025
Firm news
5 March 2025Ascend Advanced Therapies appoints John Chiminski as Chair & Karen Flynn as Independent Director
The subject's own siteobserved 3 days ago
Occurred
Feb 3, 2025
Firm news
3 February 2025AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
The subject's own siteobserved 3 days ago
Occurred
Jan 13, 2025
Firm news
13 January 2025Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program
The subject's own siteobserved 3 days ago
Occurred
Jan 6, 2025
Firm news
6 January 2025Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer
The subject's own siteobserved 3 days ago
Occurred
Nov 12, 2024
Firm news
12 November 2024Ascend Advanced Therapies Partners with EW Healthcare Partners to Expand United States Capacity and Capabilities
The subject's own siteobserved 3 days ago
Occurred
Sep 24, 2024
Firm news
24 September 2024Ascend Advanced Therapies: Continued Investment in Technology & Flexible Capacity Includes New Fill/Finish Capabilities
The subject's own siteobserved 3 days ago
Occurred
Sep 10, 2024
Firm news
10 September 2024Abingworth appoints Robert DeBenedetto as Managing Director – Clinical Co-Development
The subject's own siteobserved 3 days ago
Occurred
May 13, 2024
Firm news
13 May 2024Reneo Pharmaceuticals And OnKure Announce Proposed Merger
The subject's own siteobserved 3 days ago
Occurred
Apr 23, 2024
Firm news
23 April 2024Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-In-Class Oral MRGPR Antagonists
The subject's own siteobserved 3 days ago
Occurred
Apr 9, 2024
Firm news
9 April 2024Ascend acquires GMP manufacturing capacity in Alachua, Florida from Beacon Therapeutics
The subject's own siteobserved 3 days ago
Occurred
Mar 25, 2024
Firm news
25 March 2024Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
The subject's own siteobserved 3 days ago
Occurred
Mar 13, 2024
Firm news
13 March 2024Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System
The subject's own siteobserved 3 days ago
Occurred
Feb 12, 2024
Firm news
12 February 2024Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
The subject's own siteobserved 3 days ago
Occurred
Jan 5, 2024
Firm news
5 January 2024Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team
The subject's own siteobserved 3 days ago
Occurred
Nov 16, 2023
Firm news
16 November 2023Q32 Bio and Homology Medicines Announce Merger Agreement
The subject's own siteobserved 3 days ago
Occurred
Oct 30, 2023
Firm news
30 October 2023Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF)
The subject's own siteobserved 3 days ago
Occurred
Oct 30, 2023
Fund final close
30 October 2023Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF)
News and newswireobserved 2 days ago
$356M
Occurred
Oct 3, 2023
Firm news
3 October 2023Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA
The subject's own siteobserved 3 days ago
Occurred
Sep 21, 2023
Firm news
21 September 2023Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
The subject's own siteobserved 3 days ago
Occurred
May 10, 2023
Firm news
10 May 2023Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors
The subject's own siteobserved 3 days ago
Occurred
Dec 13, 2022
Firm news
13 December 2022Abingworth appoints experienced life sciences investor Joy Ghosh, PhD as Managing Director
The subject's own siteobserved 3 days ago
Occurred
Oct 18, 2022
Firm news
18 October 2022Anjarium Biosciences Appoints Gaurav Shah as Chairperson and Douglas Fambrough as Non-executive Director
The subject's own siteobserved 3 days ago
Occurred
Sep 2, 2022
Person left
Quentin Lionel Genghis Lloyd-Harris (Owner Of Abingworth Llp) no longer on Schedule A of Abingworth Management Inc.
Form ADVobserved 5 days ago
Occurred
Sep 2, 2022
Person left
Timothy John Haines (Owner Of Abingworth Llp) no longer on Schedule A of Abingworth Management Inc.
Form ADVobserved 5 days ago
Occurred
Sep 2, 2022
Person left
Brian Michael Gallagher (Treasurer/Director Of Abingworth Management Inc) no longer on Schedule A of Abingworth Management Inc.
Form ADVobserved 5 days ago
Occurred
Aug 15, 2022
Firm news
15 August 2022Launch Therapeutics partners with Opthea to advance OPT-302, a promising therapy for wet AMD
The subject's own siteobserved 3 days ago
Occurred
Aug 3, 2022
Firm news
3 August 2022Carlyle Completes Acquisition of Abingworth and Announces Go-forward Leadership Team; Acquisition Expands Global Healthcare Franchise with Leading Life Sciences Investment Expertise
The subject's own siteobserved 3 days ago
Occurred
Jul 12, 2022
Firm news
12 July 2022Anjarium Biosciences appoints experienced industry executives Samantha Vieira as Chief Operating Officer and Nate Massari as Chief Business Officer
The subject's own siteobserved 3 days ago
Occurred
Jul 11, 2022
Firm news
11 July 2022Glycomine Appoints Steven Axon as CEO and Adds Two New Board Directors
The subject's own siteobserved 3 days ago

Show 1 bookkeeping events

Occurred
Sep 1, 2026
Adviser CRD 157466 is not on the SEC registered or exempt adviser roster of 2026-09-01

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 office address (Form ADV), 1 website (Form ADV) · as of 2026-09-13

Emma O'Reilly
Emma O'ReillyGeneral Counsel · Revealable: 1 professional profile (firm website)
Anna Slezak
Anna SlezakSenior Associate · Revealable: 1 professional profile (firm website)
Helen Liu
Helen LiuSenior Associate, CCD · Revealable: 1 professional profile (firm website)
Ankur Shah
Ankur ShahVice President, CCD · Revealable: 1 professional profile (firm website)
Vincent Miles
Vincent MilesExecutive Director · Revealable: 1 professional profile (firm website)
Tim Haines
Tim HainesExecutive Partner · Revealable: 1 professional profile (firm website)
Travis Wilson
Travis WilsonManaging Director, CCD · Revealable: 1 professional profile (firm website)
Robert DeBenedetto
Robert DeBenedettoManaging Director, CCD · Revealable: 1 professional profile (firm website)
Andrew Sinclair
Andrew SinclairManaging Director, Head of Publics & Late Stage · Revealable: 1 professional profile (firm website)
Jayson Punwani
Jayson PunwaniManaging Director, Head of Venture · Revealable: 1 professional profile (firm website)
Bali Muralidhar
Bali MuralidharGlobal Head of Life Sciences & CIO · Revealable: 1 professional profile (firm website)
Kurt von Emster
Kurt von EmsterManaging Partner · Revealable: 1 professional profile (firm website)

Also named here, with no published line of their own (reach them through the firm): Konrad Hans von Emster (President/Director Of Abingworth Management Inc), Neil Antony Cooper (Director Of Abingworth Management Inc), John Grayson Heard (Cco/Secretary Of Abingworth Management Inc.).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Private Equity
Canonical id: dfx:pe:b8a847c0-df2f-4096-9410-32561d4447f4
First observed: Sep 13, 2026
Last observed: Sep 15, 2026 3 days ago
Source families: Federal regulator filings, Firm and issuer disclosures
3 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Abingworth Management Inc.

Private Equity

Menlo Park, CA

We are Abingworth, a trans-atlantic bio-science investment firm with a deep understanding of both the science and markets we invest in.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:b8a847c0-df2f-4096-9410-32561d4447f4

Data as of Sep 15, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 3:50 AM UTC and rebuilt at most every 15 minutes.

Fund

Vintage

Lifecycle

ADV type

Form D sold

GAV

LPs

Abingworth Clinical Co-Development Co-Investment Fund

2024

Unknown

Private Equity Fund

n/a

$57.5M

ABV 8 Strategic Uk LP

2021

Unknown

Private Equity Fund

n/a

$7.5M

Abingworth Clinical Co-Development Fund 2 Co-Investment LP

2021

Unknown

Private Equity Fund

n/a

$24.8M

Abingworth Clinical Co-Development Fund 2 LP

2021

Unknown

Private Equity Fund

n/a

$573M

Abingworth Bioventures 8 LP

2020

Harvest

Private Equity Fund

n/a

$439M

Abingworth Bioventures VII LP

2017

Unknown

Private Equity Fund

n/a

$304M

Abingworth Clinical Co-Development Fund LP

2016

Harvest

Private Equity Fund

n/a

$125M

Abingworth Bioventures V Co-Invest Growth Equity Fund LP

2015

Mature

Private Equity Fund

n/a

$10.8M

Abingworth Bioventures V LP

2015

Harvest

Private Equity Fund

n/a

$15.0M

Abingworth Bioventures VI LP

2015

Harvest

Private Equity Fund

n/a

$232M

Company

State

Role

Control

Invested

Exited

Status

Ether

n/a

unknown

n/a

unknown